课题基金 / 基金详情

项目摘要

项目成果

Edward Lakatta的其他基金

相似基金

相关文献

中文摘要
翻译
已经启动了一些需要microRNA专业知识的项目,特别是miR-200家族和miR-34 a。已经显示,miR-200家族成员(共转录的miR-200 c,-141;共转录的miR-200 b,-200 a,-429)和miR-34 a响应于氧化应激而增加,表明这些miRNA可能在与活性氧(ROS)产生增强相关的病症(如衰老和糖尿病)中发挥功能性作用。一些miR-200家族成员在人皮肤成纤维细胞和肝脏以及非人灵长类动物骨骼肌中表现出年龄相关的增加。此外,miR-200 c在老年和糖尿病啮齿动物的心肌中、糖尿病啮齿动物的股动脉中以及患有2型糖尿病和糖尿病足溃疡的患者的皮肤细胞中增加。 他指导以下正在进行的项目的构思和实施: 确定miR-200家族成员在心肌功能中的作用及其与衰老和糖尿病中收缩和舒张功能障碍的潜在联系; 确定miR-200家族成员和miR-34 a在衰老和糖尿病血管功能障碍中的作用; 建立循环miR-200家族成员在人类衰老、糖尿病、肥胖中的表达水平; 确定miR-200家族成员在骨骼肌功能中的作用。
英文摘要
Some projects that require expertise in microRNAs and, specifically, in miR-200 family and miR-34a, has been initiated. It has been shown that miR-200 family members (co-transcribed miR-200c, -141; co-transcribed miR-200b, -200a, -429) and miR-34a increase in response to oxidative stress suggesting that these miRNAs may play a functional role in conditions associated with enhanced production of reactive oxygen species (ROS) such as aging and diabetes. Some miR-200 family members exhibit an age-associated increase in human skin fibroblasts and liver, and in non-human primates skeletal muscle. Further, miR-200c increases within the myocardium of old and diabetic rodents, in femoral arteries of diabetic rodents and in skin cells of patients with type 2 diabetes and diabetic foot ulcers. He directs the conception and implementation of the following ongoing projects: Establish the role of miR-200 family members in myocardial function and its potential link to systolic and diastolic dysfunction in aging and diabetes; Establish the role of miR-200 family members and miR-34a in vascular dysfunction in aging and diabetes; Establish the expression level of circulating miR-200 family members in human aging, diabetes, obesity; Establish the role of miR-200 family members in skeletal muscle function.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A PUFA Dietary Intervention for Heart Rate
  • 批准号:
    8335786
  • 项目类别:
  • 资助金额:
    $25.83万
  • 财政年份:
    --
  • 负责人:
    Edward Lakatta
  • 依托单位:
Decreased pacemaker activity in aged sinoatrial node
  • 批准号:
    8335801
  • 项目类别:
  • 资助金额:
    $11.03万
  • 财政年份:
    --
  • 负责人:
    Edward Lakatta
  • 依托单位:
Soluble Receptor for Advanced Glycation End Products for Therapeutic Application
  • 批准号:
    8552494
  • 项目类别:
  • 资助金额:
    $12.3万
  • 财政年份:
    --
  • 负责人:
    Edward Lakatta
  • 依托单位:
Therapeutic Potential of EPO and its Derivatives for Reducing Blood Pressure
  • 批准号:
    9147229
  • 项目类别:
  • 资助金额:
    $15.43万
  • 财政年份:
    --
  • 负责人:
    Edward Lakatta
  • 依托单位:
海外基金